Optimizing the management of metastatic colorectal cancer

Pasquale Comella, Rossana Casaretti, Antonio Avallone, Luca Franco

Research output: Contribution to journalArticlepeer-review


The prognosis of patients with metastatic colorectal cancer has significantly improved in the last few years, with the introduction into the clinical practice of new cytotoxic treatments, the availability of non-cross resistant agents after the front-line treatment failure, and the combination of targeted agents (i.e., the inhibitors of the epidermal growth factor and vascular endothelial growth factor pathways) with conventional drugs. All these options must be incorporated into a complex strategy of management, in which a customized management according to the disease status, with an intensified induction approach followed by maintenance (and reinduction), should be investigated.

Original languageEnglish
Pages (from-to)15-26
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Jul 2010


  • Bevacizumab
  • Cetuximab
  • Cytotoxic drugs
  • Management
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)


Dive into the research topics of 'Optimizing the management of metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this